Eight randomised trials of 664 patients with schizophrenia spectrum or bipolar disorder on antipsychotics were pooled to assess added GLP-1 receptor agonists. Body weight fell by 6.74 kg against control, and HbA1c by 0.61 percentage points. Overall and serious adverse events did not differ, although nausea, vomiting and constipation were more frequent on GLP-1 treatment.
Why it is interesting: Pooled trial evidence in a group with reduced life expectancy, on weight and blood glucose rather than deaths.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.